The QualityStocks Daily Friday, March 3rd, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(OBSV) $0.2300 +116.98%

HempWire(HEMP) $0.0004 +33.33%

QualityStocks(ARDX) $3.8200 +32.18%

The QualityStocks Daily Stock List

ObsEva S.A. (OBSV)

MarketBeat, InvestorPlace, StockMarketWatch, MarketClub Analysis, The Stock Dork, Trades Of The Day, TraderPower, StreetInsider, QualityStocks, BUYINS.NET, Schaeffer's, and Early Bird reported earlier on ObsEva S.A. (OBSV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ObsEva S.A. (NASDAQ: OBSV) (FRA: 22D) is a biopharmaceutical firm that is engaged in developing and commercializing new therapeutics for women who suffer from severe conditions which affect pregnancies and reproductive health.

The firm has its headquarters in Geneva, Switzerland and was incorporated in 2012, on November 14th by André Chollet and Ernest Loumaye. It operates as part of the scientific research and development services industry, under the health care sector. The firm has three companies in its corporate family and serves consumers around the globe.

The company is working to develop therapeutic solutions for women aged between 15 and 49 who suffer from reproductive conditions that impact their ability to conceive, their quality of life and/or complicate pregnancy and the health of newborns.

The enterprise’s product pipeline comprises of an oral oxytocin receptor antagonist dubbed Nolasiban, which improves live birth rates and clinical pregnancy in women undergoing IVF; and an oral and selective PGF2a receptor antagonist or prostaglandin F2a known as Ebopiprant, which has been developed as a treatment to be ingested once a day for pre-term labor between week 24 and 34 of the gestational period. The enterprise also develops a gonadotropin-releasing hormone receptor antagonist dubbed Linzagolix, which has been designed to treat heavy menstrual bleeding linked to uterine fibroids in women who haven’t reached menopause and pain linked to endometriosis.

The firm recently filed an NDA application for its Linzagolix formulation to the FDA, for the treatment of uterine fibroids. The formulation’s success will not only meet the needs of patients with fibroids but also encourage more investments into the firm, which will have a positive effect on the company’s growth.

ObsEva S.A. (OBSV), closed Friday's trading session at $0.23, up 116.9811%, on 197,590,054 volume with 00 trades. The average volume for the last 3 months is 53.152M and the stock's 52-week low/high is $0.08 /$2.14 .

Ardelyx (ARDX)

MarketBeat, MarketClub Analysis, InvestorPlace, TradersPro, Schaeffer's, QualityStocks, StockMarketWatch, Investors Alley,, Zacks, TopPennyStockMovers, PoliticsAndMyPortfolio, TraderPower, The Street, Barchart, OTCtipReporter, Trades Of The Day, Daily Stocks, Dynamic Wealth Report, Market Report, Jason Bond, Daily Trade Alert, BUYINS.NET, Penny Stock, PennyStockScholar, Profitable Trader Authority, Street Insider, StreetInsider, The Stock Dork, Top Pros' Top Picks, TradersPro Morning and PennyStockProphet reported earlier on Ardelyx (ARDX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ardelyx Inc. (NASDAQ: ARDX) (FRA: 41X) is a biopharmaceutical firm that is engaged in the development and sale of medications for treating cardirenal and kidney ailments.

The firm has its headquarters in Fremont, California and was incorporated in 2007, on October 17th by Jean M. Frechet, Peter G. Schultz and Domonique Charmot. Prior to its name change in June 2008, the firm was known as Nteryx Inc. It operates as part of the healthcare sector, in the biotech and pharma sub-industry and serves consumers across the globe.

The company develops molecules that target receptors and transporters and modulate nutrient uptake or cause the secretion of key hormones, in order to produce a therapeutic benefit in patients. Unlike these systemic products, non-systemic products act from inside the intestines, in order to avoid possible side effects that occur with systemic exposure.

The enterprise’s pipeline comprises of a small molecule program known as RDX020, developed to treat metabolic acidosis; and a small potassium secretagogue molecule program dubbed RDX013, which is currently undergoing a phase 2 clinical trial assessing its effectiveness in treating hyperkalemia. In addition to this, the enterprise also develops a formulation known as tenapanor, which is undergoing a phase 3 clinical trial testing its effectiveness in treating hyperphosphatemia in patients with end-stage renal disease who are on dialysis. The formulation recently concluded phase 3 clinical trials evaluating its efficacy in treating irritable bowel syndrome in patients with constipation.

The company may soon receive approval from the FDA for an NDA application for it tenapanor formulation after it resolves the deficiencies observed in its review. The formulation’s success will not only boost the company’s growth but also encourage investments into the firm.

Ardelyx (ARDX), closed Friday's trading session at $3.82, up 32.1799%, on 53,177,998 volume with 00 trades. The average volume for the last 3 months is 33,953 and the stock's 52-week low/high is $0.4902 /$3.98 .

Tremor International (TRMR)

Wall Street Resources, The Street, StreetInsider, MarketBeat, StreetAuthority Daily, Street Insider, SmallCapNetwork, and InvestorPlace reported earlier on Tremor International (TRMR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tremor International Ltd (NASDAQ: TRMR) (OTC: TTTPF) (LON: TRMR) (FRA: 7P90) is a company engaged in the provision of end-to-end software platforms that allow advertisers to reach relevant publishers and audiences.

The firm has its headquarters in Tel Aviv-Yafo, Israel and was incorporated in 2007, on March 20th. Prior to its name change in September 2015, the firm was known as Taptica International Limited. It operates as part of advertising agencies industry, under the communication services sector. The firm serves consumers around the globe.

The enterprise helps advertisers deliver impactful brand stories across all screens through the power of innovative video technology combined with advanced audience data and captivating creative content. Its demand side platform (DSP) provides full-service and self-managed marketplace access to advertisers and agencies in order to execute their digital marketing campaigns in real time across various ad formats. Its sell supply side platform (SSP) provides access to data and a comprehensive product suite to drive inventory management and revenue optimization. The enterprise also provides a data management platform solution, which integrates DSP and SSP solutions enabling advertisers and publishers to use data from various sources in order to optimize results of their advertising campaigns. It serves Ad buyers, advertisers, brands, agencies, and digital publishers in Israel, the Asia-Pacific, the United States, the Middle East, Europe and Africa.

The company recently entered into a strategic partnership with Upwave, a leading analytics platform for brand advertising. This will help extend its consumer reach while also opening the company up to new growth and investment opportunities.

Tremor International (TRMR), closed Friday's trading session at $7.68, up 1.1858%, on 33,953 volume with 00 trades. The average volume for the last 3 months is 2,716 and the stock's 52-week low/high is $6.12 /$16.73 .

Network International (NWITY)

MarketBeat reported earlier on Network International (NWITY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Network International Holdings PLC (OTC: NWITY) (LON: NETW) (FRA: NIH) is a digital commerce enabler that is focused on providing technology-enabled payment solutions to merchants and financial institutions of all sizes and types.

The firm has its headquarters in Dubai, the United Arab Emirates and was incorporated in 1994. It operates as part of the software-infrastructure industry, under the technology sector. The firm primarily serves consumers in Africa and the Middle East.

The company operates through Middle East and Africa segments. The Middle East segment provides merchant solutions and issuer solutions to various financial and non-financial institutional clients in the UAE, Jordan, and Saudi Arabia. The Africa segment offers services to Egypt, Kenya, and South Africa.

The enterprise provides merchant solutions, which include payment solutions, such as N-Genius payment device, N-Genius mini payment device, and On-the-Go payment device; N-Genius online, buy now pay later, and DPO pay online payment solutions; and retail integrated and hospitality solutions. It also offers value-added services, including SmartView interactive dashboards, SmartView performance report, dynamic currency conversion, multicurrency online, easy payment plan, 3D secure, and network self-services; and acquiring processing and smart bundle solutions. In addition, the enterprise provides card and processing solutions comprising prepaid card, debit and credit card, and commercial card solutions; loyalty solutions; instant issuance, 3D secure, card control, SmartView, API, and payment plan services; fraud solutions; and issuer services.

The company is in advanced talks to acquire Mashreqbank PSC’s payments unit, which will not only extend its consumer reach but also bring in additional revenues and investments to the company.

Network International (NWITY), closed Friday's trading session at $3.47, up 0.872093%, on 2,716 volume with 00 trades. The average volume for the last 3 months is 4,300 and the stock's 52-week low/high is $2.056 /$4.48 .

Rupert Resources (RUPRF)

MarketBeat, Trades Of The Day and Daily Trade Alert reported earlier on Rupert Resources (RUPRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rupert Resources Ltd (OTCQX: RUPRF) (FRA: ROS) is a gold exploration and development firm that is focused on acquiring and exploring for mineral properties in Finland.

The firm has its headquarters in Toronto, Canada and was incorporated in 1981, on February 11th. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers in Canada.

The company’s primary focus is the Rupert Lapland Project in the Central Lapland Greenstone Belt in Northern Finland. It operates in one reportable operating segment, being the acquisition and exploration of mineral properties in Finland.

The enterprise’s flagship projects include its 100% owned Ikkari discovery and the Pahtavaara mine and millin Northern Finland. Ikkari is a gold discovery zone that is part of its Rupert Lapland Project, which also includes the Pahtavaara gold mine, mill, and exploration permits and concessions within a total land package of 595km2. The project is located in the Central Lapland Greenstone Belt of Northern Finland (Pahtavaara). The enterprise also holds a 100% interest in the Surf Inlet Property in British Columbia, a 100% interest in properties in Central Finland and a 20% carried participating interest in the Gold Center property located adjacent to the Red Lake mine in Ontario.

The company, which recently announced its latest financial results, remains focused on making and advancing discoveries of scale and quality with high margin and low environmental impact potential. This will positively influence revenues and investments into the company.

Rupert Resources (RUPRF), closed Friday's trading session at $3.51, up -1.9553%, on 4,300 volume with 00 trades. The average volume for the last 3 months is 432,831 and the stock's 52-week low/high is $2.63 /$5.37 .

LanzaTech Global (LNZA)

The Stock Dork reported earlier on LanzaTech Global (LNZA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LanzaTech Global Inc. (NASDAQ: LNZA) is a nature-based carbon refining firm that is engaged in the provision of carbon recycling technology.

The firm has its headquarters in Skokie, Illinois and was incorporated in 2005. It operates as part of the waste management industry, under the industrials sector. The firm serves consumers in Europe, North America, Australia and Asia.

The company's goal is to challenge and change the way the world uses carbon, enabling a new circular carbon economy where carbon is reused rather than wasted, skies and oceans are kept clean, and pollution becomes a thing of the past. Carbon emissions are fed to trillions of carbon-hungry microbes that turn pollution into valuable raw material commodities.

The enterprise is focused on its LanzaTech technology and its CarbonSmart IP licensing services. It develops gas fermentation technology designed to offer a profitable pathway for alleviating the significant carbon problem of heavy industry and manufacturing. It transforms waste carbon into materials such as sustainable fuels, fabrics, packaging, and other products. Its carbon recycling technology is like retrofitting a brewery onto an emission source like a steel mill or a landfill site, but instead of using sugars and yeast to make beer, pollution is converted by bacteria to fuels and chemicals. The enterprise has 3 commercial plants currently in operation in China.

The firm recently signed a collaboration agreement with the Abu Dhabi Waste Management Company to develop a large-scale conversion plant for transforming solid municipal waste into sustainable alternative fuel. This move will not only extend the firm’s consumer reach but also generate additional revenues for the firm and value for its shareholders.

LanzaTech Global (LNZA), closed Friday's trading session at $3.65, up -4.4503%, on 433,117 volume with 00 trades. The average volume for the last 3 months is 1,670 and the stock's 52-week low/high is $3.40 /$10.80 .

Western Forest Products (WFSTF)

MarketBeat, Trades Of The Day, StreetInsider and Daily Trade Alert reported earlier on Western Forest Products (WFSTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Western Forest Products Inc. (OTC: WFSTF) (TSE: WEF) (FRA: NWF) is an integrated forest products firm that is focused on the manufacture of wood products and managing forests sustainably.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1955. It operates as part of the lumber and wood production industry, under the basic materials sector. The firm serves consumers around the globe, with a focus on Japan and North America.

The coastal woodland operator company meets the needs of consumers globally with a specialty wood products focus and diverse product offering. Its large investment in manufacturing and progressive approach to safe and sustainable forestry practices ensures the health and prosperity of its business, forests and communities for generations to come. The company builds with natural wood products to help reduce greenhouse gases.

The enterprise is involved in timber harvesting, sawmilling logs into specialty lumber, value-added lumber and glulam remanufacturing, and wholesaling purchased lumber activities. It provides an impressive range of appearance, structural and industrial wood products destined for both local and international markets. The enterprise’s products have applications in outdoor living, exterior appearance, interior living, industrial, and structural applications. All its natural wood products are recyclable and biodegradable and come from sustainably managed forests.

The firm, which recently announced its latest financial results, is focused on investing in equipment and technology to produce higher-value products and improving its operating efficiency. This will positively influence revenues into the firm as well as its overall growth.

Western Forest Products (WFSTF), closed Friday's trading session at $0.9, up -0.044425%, on 1,670 volume with 00 trades. The average volume for the last 3 months is 140,819 and the stock's 52-week low/high is $0.7894 /$1.80 .

Treasure Global Inc. (TGL)

Super Stock Picker, Streetwise Reports and QualityStocks reported earlier on Treasure Global Inc. (TGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Treasure Global (NASDAQ: TGL), an innovative e-commerce platform providing seamless technology enabled solutions for lifestyle needs, has signed an agreement with a single institutional investor for an unsecured convertible debt facility. The agreement is for up to $5.5 million to be drawn in tranches. According to the announcement, Treasure Global anticipates using the first $2 million drawdown to continue developing innovative new products and solutions as well as for working capital and general corporate purposes. “We are pleased to reach an agreement for financing of up to $5.5 million, to provide TGI with additional runway to continue the development of our pipeline of innovative technology offerings for lifestyle needs,” said Treasure Global CEO Sam Teo in the press release. “The additional capital will provide TGI with greater financial flexibility as we remain focused on increasing user engagement and enhancing our product offerings to generate revenue with improved margins.”

To view the full press release, visit

About Treasure Global Inc.

Treasure Global is an innovative Malaysian e-commerce platform providing seamless technology enabled solutions for lifestyle needs with instant rebates and affiliate cashback programs. On a mission to bring together the worlds of online e-commerce and offline physical retailers, TGI is developing a portfolio of leading digital platforms for use throughout Southeast Asia and Japan. In June 2020, TGI launched its proprietary product, the ZCITY App, a unique digital ecosystem that transforms and simplifies the e-payment experience for consumers while simultaneously allowing them to earn rewards. In the ZCITY ecosystem, users can utilize TAZTE, a revenue-generating digital F&B management system providing merchants with a one-stop touchless management and automated solution to digitalize their businesses. As of Dec. 31, 2022, ZCITY had more than 2,300,000 registered users. For more information about the company, visit

Treasure Global Inc. (TGL), closed Friday's trading session at $1.53, up -5.5556%, on 141,125 volume with 00 trades. The average volume for the last 3 months is 1.434M and the stock's 52-week low/high is $1.40 /$19.80 .

HIVE Blockchain Technologies Ltd. (HIVE)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat, StreetInsider, Early Bird,, StockMarketWatch, Greenbackers, Hit and Run Candle Sticks, Barchart, Stock Market Watch, WealthMakers, StockOodles, StreetAuthority Daily, The Night Owl, The Online Investor, TopStockAnalysts, Wall Street Resources and smartOTC reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Technological advances have birthed innovative solutions in a myriad of industries. Blockchain and artificial intelligence (AI) are the trailblazers of our time, with the potential to upscale how we go about our daily businesses, and when these two are merged, they have such a synergy to catalyze revolutionary solutions.

Understanding AI and Blockchain synergy

AI mainly deals with the creation of intelligent machines, which can perform duties that otherwise require the input of human intelligence. Blockchain is a decentralized ledger allowing secure and transparent transactions to take place. The amalgamation of these two technologies is a potential trendsetter for most industries.

Applications fusing blockchain and AI in select industries

Blockchain and AI synergy can be supported to create innovative solutions in a myriad of industries.

Supply chains: AI and Blockchain can improve the management of supply chains by boosting transparency, reducing waste, promoting sustainability and reducing fraud risks. For example, AI algorithms enable Walmart supermarket to track produce from the farm to its stores, ensuring high-quality and safe produce. This helps Walmart curb foodborne outbreaks coming from contaminated produce.

GamingAI and blockchain can create platforms for online gaming where players can own, manage and trade their virtual assets. These technologies have also provided better experience in terms of user functionality and performance on the gaming platforms, providing fresh opportunities for both players and investors to venture into. An example is Axie Infinity, which taps AI and blockchain to make game recommendations which are personalized.

Management of digital identity: The two giant techs applied in the digital identity market reducing fraud risks though management and verification of identity data, thus increasing trust from the users. Civic and Self Key are examples of such companies leveraging these technologies to increase fraud detection and avert identity theft.

Other industries that could benefit greatly using these technologies include the following:

  • Real estate- to aid in management and sale of real estate properties
  • Public services, such as manage voting during elections and keep public records in a bid to enhance accuracy and efficiency
  • Human resource sectors where recruitment processes can be streamlined and optimized while employee data and employment records can be verified efficiently. Some companies that have utilized this convergence in this space include Chronobank and HumanCoin. 

AI and blockchain synergy has the potential to revolutionize industries that will adapt to it, and innovative solutions using these technologies can bring about better security, clarity and accountability. This can, in turn, be a global game changer.

As enterprises such as HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) deepen their penetration, more sectors could find blockchain and AI use cases indispensable to their operations.

HIVE Blockchain Technologies Ltd. (HIVE), closed Friday's trading session at $2.75, up -2.1352%, on 1,434,374 volume with 00 trades. The average volume for the last 3 months is 1.028M and the stock's 52-week low/high is $1.36 /$11.70 .

Warrior Met Coal Inc. (HCC)

The Online Investor, MarketBeat, QualityStocks, StreetInsider, Market Report, Zacks, The Street, Trades Of The Day, Daily Trade Alert, DividendStocks, BUYINS.NET, StockMarketWatch, InvestorPlace, Schaeffer's, StreetAuthority Daily, MarketClub Analysis, AllPennyStocks, Market Intelligence Center Alert, SmarTrend Newsletters, Street Insider, Dividend Report, TopStockAnalysts, CRWEFinance and TradersPro reported earlier on Warrior Met Coal Inc. (HCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recently released report from the Center for Research on Energy and Clean Air (CREA) and Global Energy Monitor (GEM) has revealed that despite global efforts to decarbonize, China is moving forward with coal energy. The report shows that China is quickly approving and erecting new coal-fired power plants amid a global climate-change crisis and in spite of the country’s own promises to step away from coal.

China approved an average of two new coal-fired power plants per week in 2022, undermining the country’s coal promises and underscoring its increasing reliance on coal for energy generation. GEM research analyst Flora Champenois stated that China’s actions were a contradiction to the global decline of power generation using coal.

Although the energy source played a crucial role in the industrialization of most of the world, decades’ worth of research has revealed that it was also instrumental in heating up the atmosphere and accelerating climate change.

Champenois noted that China has approved new coal power plants with astonishing speed, explaining that new projects are beginning, gaining permits, obtaining capital and breaking ground in months.

China is currently responsible for close to 30% of the world’s carbon emissions, and the country produces two times more emissions than the United States. The Asian country approved new projects worth 106 gigawatts of capacity in 82 different sites throughout 2022, quadrupling the amount of capacity that received approval in 2021.

Leaders of countries around the world were forced to look to alternative energy sources last year after an incredible heat wave and drought impacted hydropower generation facilities and caused power shortages. Since hydropower generation is the second-largest source of energy in China, reduced output forced power generators to fire up coal-power plants to make up for the shortfall.

Coal consumption increased throughout the year and peaked in August when power plants burnt through 8.16 million tons of thermal coal daily.

The country’s reliance on coal increased from 2021 to 2022 when coal power generation increased by 22% and accounted for 69% of China’s total energy mix. Coal-fired electricity accounted for 67.4% of the total power supply in 2021, and even though authorities shut down hundreds of coal mines, the remaining ones were instructed to produce as much coal as possible due to countrywide energy shortages.

On the other hand, China added around 125 gigawatts of wind and solar capacity in 2022, bringing the total share of renewables to only 2%. The report noted that while the increase was noteworthy, it would not be enough to supply energy demand growth without the help of fossil fuels. If China is to truly reduce its carbon emissions, the report asserts, it would have to start phasing out its “vast coal power plant fleet” instead of growing it.

Looking at things from China’s perspective, it is a tough choice not to ramp up coal production when the country is staring an energy crisis in the face. Hard decisions have to be made, which is why it isn’t surprising that the revenues of coal companies elsewhere, including Warrior Met Coal Inc. (NYSE: HCC), are seeing an uptick at this time when global energy supply chains are under immense strain.

Warrior Met Coal Inc. (HCC), closed Friday's trading session at $42.44, up 4.0451%, on 1,028,570 volume with 00 trades. The average volume for the last 3 months is 233,631 and the stock's 52-week low/high is $26.11 /$42.95 .

Kandi Technologies Group Ltd. (KNDI)

Green Car Stocks, MarketClub Analysis, InvestorPlace, QualityStocks, Schaeffer's, The Street, StockMarketWatch, Hit and Run Candle Sticks, StreetInsider, TraderPower, Greenbackers, Jason Bond, Alternative Energy, GreatStockPix, Wall Street Resources, China Stock Alerts, MarketBeat, BUYINS.NET, Investing Futures,, Money Morning, Penny Stock Rumble, ProfitableTrading, TradersPro, SmarTrend Newsletters, StreetAuthority Daily, Trades Of The Day, TradingMarkets, TopStockAnalysts, FeedBlitz, Energy and Capital, Dynamic Wealth Report, DrStockPick, Money and Markets, CRWEWallStreet, Street Insider, CRWEPicks, CRWEFinance, CoolPennyStocks, ChartAdvisor, Weekly Wizards, BullRally, BestOtc, Barchart, Daily Trade Alert, StockEgg, Profit Confidential, PennyTrader Publisher, PennyToBuck, PennyStockVille, PennyOmega, PennyInvest, SmallCapNetwork, SmallCapVoice, HotOTC, Stock Traders Chat, Market Report, MadPennyStocks, StockHotTips, InvestorsUnderground, Investors Alley, StockRich, InvestorGuide, Investor Ideas, Rick Saddler and Willy Wizard reported earlier on Kandi Technologies Group Ltd. (KNDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In an effort to catch up in an industry dominated by automakers such as Tesla, Nissan has increased its sales targets for electrified vehicles and unveiled a number of forthcoming all-electric and e-Power hybrid vehicles that are already in development, as well as plans to enhance American powertrain manufacturing.

The Japanese automaker, which pioneered the EV market with its Leaf all-battery model, had struggled as have many other legacy automakers as a result of growing rivalry from more agile newcomers.

But now, Nissan has promised that it would introduce 27 brand new electric vehicles (EVs), 19 of those being fully electric vehicles in contrast to the 23 electric vehicles, which include 15 new electric vehicles that the company had originally anticipated when it unveiled its Nissan Ambition 2030 goal in 2021. In addition to the planned increase of electric vehicles, Nissan revised its projections for the composition of sales. The planned EV sales across the globe have been raised to 44% from the prior goal of 40% by the year 2026. The company intends to sell fewer traditional models as well. Nissan anticipates that about 44% of its worldwide sales will be electric vehicles by 2026.

Nissan and Infiniti’s sales of electric vehicles are expected to increase from their earlier goal of 50% to 55% by the year 2030, according to the company. Take note that by 2030, Nissan plans to sell only electric vehicles in the United States.

Nissan asserts that its new, revised approach is a response to customers’ shifting needs and the economic outlook. However, the reality is that the planned additional increase of electric vehicles was facilitated by Nissan’s renewed partnership with Renault, which resulted in a more equitable working relationship between the two companies and paved the way for new opportunities for sharing components as well as development costs.

Ashwani Gupta announced on Monday that Nissan also wants to construct electrical power systems at its Decherd facility along with the manufacture of electric vehicles at its Tennessee facility in Smyrna to help comply with IRA regulations. According to Gupta, Nissan is considering adding a second U.S.-made battery source to supplement the supply it currently receives from Envision AESC. The company is convinced that localizing the production of batteries beginning in 2026 will result in IRA compliance. While that compliance can be quite challenging, it presents a chance to increase the EV market competition.

With legacy automakers such as Nissan upping their game, startups such as Kandi Technologies Group Ltd. (NASDAQ: KNDI) might be well advised to pay attention if they wish to claim a sizeable share of the global electric vehicle market for years to come.

Kandi Technologies Group Ltd. (KNDI), closed Friday's trading session at $2.46, up 5.1282%, on 233,874 volume with 00 trades. The average volume for the last 3 months is 1.092M and the stock's 52-week low/high is $2.00 /$3.75 .

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report, Uncommon Wisdom,, MarketClub Analysis, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, PennyOmega, BestOtc, Schaeffer's, StockHotTips, TraderPower, PennyToBuck, StockOodles, Street Insider, The Street and TopPennyStockMovers reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Psychedelics are poised to revolutionize the psychiatric industry over the next couple of decades. In the midst of a global mental health crisis that has affected more than a billion people around the world, researchers have been working to develop psychedelic-assisted therapies to treat a myriad of mental health disorders.

Research has revealed that psychedelics can treat the symptoms of conditions such as post-traumatic stress disorder, treatment-resistant depression, anxiety and even eating disorders. Furthermore, prior studies have shown that psychedelics can deliver long-term benefits at relatively small doses and with hardly any negative side effects.

A recent study has now revealed that mystical psychedelic experiences could boost mental health by reducing the symptoms of anxiety and depression. The study is among the first efforts to categorize the subtypes of psychedelic experiences and connect them with their respective mental health outcomes.

Researchers reviewed data collected from a poll of close to 1,000 respondents who discussed their prior recreational experiences with hallucinogenic drugs. Most of the participants reported using LSD, mescaline, psilocybin, peyote cactus,  5-MeO-DMT or ayahuasca.

Based on the study’s findings, it seemed that individuals who had the highest scores in the “mystical and insightful nature” section of the questionnaires reported consistent improvements in their depression and anxiety symptoms. Researchers also analyzed the level of anxiety and depression symptoms as well as life satisfaction and psychological flexibility levels.

The respondents filled out questionnaires that evaluated how mystical, psychologically insightful and challenging their psychedelic experiences were.

Study coauthor Aki Nikolaidis stated that the group reporting the highest mystical and insightful experiences coupled with low challenging experiences had the biggest reduction in anxiety and depression symptoms. Mystical experiences were also associated with boosted mental health when the researchers only analyzed data from participants who had just used LSD or psilocybin.

Participants who had high mysticism and insight scores and low challenge scores were more likely to be younger. Furthermore, participants with high scores on challenging experiences tended to have taken large amounts of hallucinogenic drugs.

Nikolaidis noted that analyzing the different subtypes of psychedelic experiences regardless of the specific type of hallucinogenic used “answers an interesting question.” According to Nikolaidis, the fact that these subtypes seem to have a correlation with specific outcomes underscored the importance of understanding how psychedelics act upon the human mind and how these effects can be harnessed for therapeutic purposes.

The study’s findings were reported in the “Journal of Affective Disorders.

In addition to these individual studies, companies such as atai Life Sciences N.V. (NASDAQ: ATAI) are also doing their own research on these hallucinogens. We are likely to find out much more about how these substances affect the brain to deliver the diverse results that preliminary studies point to.

atai Life Sciences N.V. (ATAI), closed Friday's trading session at $1.56, up 0.645161%, on 1,092,506 volume with 00 trades. The average volume for the last 3 months is 18,511 and the stock's 52-week low/high is $1.45 /$5.81 .

The QualityStocks Company Corner

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

During interview, Vajdic recounts first steps of journey in theUnited States

CEO points to key lessons he learned that helped him foundHeartBeam

The company has developed the first and only 3D-vector 12-leadelectrocardiogram (“ECG”) platform for heart attack detectionanytime, anywhere

Growing up in Yugoslavia (now Serbia) as the only child of awell-known surgeon, HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, felt some pressure to studymedicine and follow in his father’s footsteps. One day, at hisfather’s insistence, Vajdic observed a surgery — and fainted themoment he saw the first drop of blood. While that experienceconfirmed to Vajdic that medicine was not for him, decades later heis making his mark in the field of the detection and treatment ofheart attacks.

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.


HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Friday's trading session at $3.33, up 2.7778%, on 18,611 volume with 00 trades. The average volume for the last 3 months is 121,060 and the stock's 52-week low/high is $1.12 /$6.74 .

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) announced that its common shares will begin trading on the TorontoStock Exchange at market opening on Monday, March 6, 2023; theshares will trade under the company’s current trading symbol ELO.At the same time, ELO shares will be delisted from the TSX VentureExchange. “We are pleased to have graduated to the premier Canadianexchange,” said Eloro Resources CEO Thomas Larsen in the pressrelease. “Listing on the TSX will provide Eloro greater marketvisibility and increased access to capital to help drive thecompany’s growth as it advances its flagship Iska Iska project insouthern Bolivia.”

To view the full press release, visit

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Friday's trading session at $2.61, up 6.0976%, on 121,060 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $6.74 /$.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing andcommercializing innovative immunotherapeutic products, is workingon changing the grim reality caused by the evolution of COVID-19.“The company’s leading inhaled nanosized antibody (‘NanoAb’)candidate, which is currently being prepared for clinical trials,has shown neutralization of all relevant Omicron subvariants…Developed in collaboration with Germany-based Max Planck Institutefor Multidisciplinary Sciences (‘MPI’) and the University MedicalCenter Göttingen (‘UMG’), the alpaca-derived NanoAbs havedemonstrated unique characteristics such as greater formulationadvantages, stability at high temperatures, and binding affinitythan monoclonal antibodies (‘mAbs’). Moreover, NanoAbs have shownstrong potential for superior clinical outcomes, safety and patientconvenience at lower costs than mAbs, which have generated billionsin annual commercial sales,” a recent article reads. “Indeed, theemergence of new variants remains a concern, and NanoAbtherapeutics have the potential to quickly and effectively addressnew variants,” CEO Amir Reichman is quoted as saying. “Ourcollaborators [at MPI and UMG] have generated libraries each with~300 million COVID-19 NanoAb candidates, as compared to mAblibraries that contain only thousands of options. Thus, as newvariants emerge, we would expect to be in a position to rapidlydevelop a new neutralizing NanoAb.”

To view the full article, visit

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Friday's trading session at $2.3038, up 2.8482%, on 120,627 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $2.12 /$22.90 .

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) andblue light emergency communication systems, has announced itsreceipt of a purchase order for 30 new K1 Blue Light Towers from aFlorida-based reseller of Knightscope technologies. Theannouncement reads, “K1 Blue Light Tower emergency phones delivercompletely wireless communications, 24/7/365, even in harsh weatherconditions. Each device provides clear, reliable voiceconnectivity, the familiar flashing blue strobe, and night areaillumination to assist responders in locating callers. Solar powerand a public address warning speaker is also available.” To viewthe full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Friday's trading session at $1.15, up 0.877193%, on 320,602 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $1.03 /$6.75 .

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

The PDAC convention has grown since 1932, becoming the choice eventfor the world’s mineral industry, hosting more than 1,100exhibitors and 2,500 investors

Ucore’s presentation will focus on its RapidSX(TM) technology whichprovides a North American opportunity in the REE industry, removingdependency from China’s current industry domination

Ucore is currently working on near-term and long-term processingfacilities in Canada, Alaska, and Louisiana

Registration for the world’s premier mineral exploration and miningconvention, PDAC 2023, is currently open for attendees. Theconvention is known for attracting up to 30,000 attendees from over130 countries, providing educational programming, network events,outstanding business opportunities, and fun.Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is pursuing the exploration, separation and scalable production ofrare earth elements (“REE”) in Canada and the U.S. “Ucore RareMetals is focused on becoming a leading advanced technology companythat provides best-in-class metal separation products and servicesto the mining and mineral extraction industry. Through strategicpartnerships, Ucore’s plan is to counteract China’s control of theNorth American REE supply chain through the near-term developmentof a heavy and light rare-earth processing facility in Louisiana,with subsequent additional Strategic Metals Complexes (‘SMCs’), andthe longer-term development of a heavy-rare-earth-element mineralresource property at Bokan Mountain on Prince of Wales Island,Alaska,” a recent article reads. “In 2020, Ucore acquiredInnovation Metals Corp. and its RapidSX separation technologyplatform, focused on the production of commercial-grade, separatedrare earth elements at scale… The RapidSX technology significantlyimproves the well-established, well-understood and provenconventional separation methods currently in use. In addition, anintegral part of Ucore’s growth plan centers around environmental,social, and governance (‘ESG’) criteria, which brings vastenvironmental advantages to metals processing compared to thecurrent technology in China.” To view the full article, visit

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is engaged in Rare Earth Element (REE) resource development and in commercializing its critical metals separation technology, RapidSX™, for the mining and metals extraction industry. The company is guided by principles of environmental, social and corporate governance (ESG) with a focus on disrupting China’s current dominance of the U.S. REE supply chain.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. It plans to aid in the development, through strategic partnerships, of a North American REE supply chain controlled by the U.S. and its allies.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Friday's trading session at $1.05, up 1.9417%, on 19,732 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.40 /$1.14 .

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

The total marijuana sales in Arizona in 2022 were similar to thosein 2021, the first year the drug was legal for adult use, but theroutes by which each year’s sales reached $1.4 billion were remarkably different. In 2021, medical cannabis sales accounted for $760 million, or nearly 55% of total sales. In 2022, recreational marijuanatook the lead, accounting for roughly 70% of total sales, totalingmore than $950 million. The medical cannabis market has dropped tojust over $500 million. Recreational cannabis sales ended 2022 withits best monthly total in December, totaling about $86.6 million, asmall increase from the $85.8 million in the previous month. Themonthly sales of medical marijuana remained stable, falling from$31.9 to $31.1 between November 2022 and December 2022. Since thebeginning of the legalization of adult-use in January 2021,cannabis sales have totaled $2.9 billion in both markets. SinceApril 2021, medical sales have decreased almost every month, with afew exceptions, such as July, when sales reached $71.6 millionfollowing a $5 million decline in June. As these marijuana salesfigures climb, there is likely to be a commensurate increase in theuse of cultivation equipment such as that sold by Advanced Container Technologies Inc. (OTC: ACTX), given that rising sales point to an increase in the produce beingcultivated and processed.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.32, up 0%, on 2 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005 /$1.25 .

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologieswith a focus on monitoring and modulating the immune system,announced that it is working with Riverside Management Group LLC, amerchant banking firm providing investment banking advisoryservices; RMG will be supporting Aditxt’s strategic growth andrevenue generating plans for its subsidiary Pearsanta Inc., as wellas other Aditxt programs. The company noted that Pearsanta wasformed to accelerate the growth of AditxtScore(TM) and focused onexpanding the market through new offerings and customeracquisitions. A AditxtScore is the company’s exclusive platformdesigned offer a personalized profile of the immune system based onthe body’s ability to respond to viruses, bacteria, allergens andmore. “We are pleased to partner with Riverside Management Groupand its team of investment and financial advisory experts,” saidAditxt cofounder, chair and CEO Amro Albanna in the press release.“We’ve mandated Riverside Management Group to focus on strategic,growth-driven M&A opportunities for Pearsanta and other currentand future programs. We believe Pearsanta is well-positioned toachieve meaningful financial milestones in 2023 and look forward tosharing highlights with our valued Aditxt shareholders.”

To view the full press release, visit

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.


AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.


ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.

Aditxt Inc. (NASDAQ: ADTX), closed Friday's trading session at $1.14, up -3.3898%, on 29,370 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $1.00 /$28.49 .

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra willbe participating together on a panel at the upcoming South bySouthwest(R) (SXSW) Conference; the title of the panel is “OpenMinds: Innovations in Consciousness, Psychedelics & MentalHealth.” The SXSW event is slated for March 10–19, 2023, and willbe held in Austin, Texas. The panel that Drysdale and Chopra areparticipating on is scheduled for March 12 at 11:30 a.m. CT.According to the announcement, other panel members include CristieStrongman MA, EdM, a psychotherapist at the MultidisciplinaryAssociation for Psychedelic Studies (MAPS), and GabriellaWright, cofounder of the Never Alone Alliance. The panel memberswill be exploring the connection between consciousness, mentalhealth and psychedelic therapeutics along with the need forhumanity to focus on the internal work required to heal. These sameindustry experts are also part of an upcoming miniseries, titled“Open Minds: Exploring Psychedelic Medicine. ”The six-part programwill look at topics such as consciousness, the experience of usingpsychedelic treatments, the current research landscape and what thefuture of mental healthcare may look like. The miniseries alsofeatures researcher Dennis McKenna, who has conductedinterdisciplinary research on the ethnopharmacology of Amazoniantraditional medicines for more than 40 years; Bryan Johnson,founder and CEO of Kernel; Keith Ferrazzi, founder and chair ofFerrazzi Greenlight; and Adam Strauss, comedian and psychedelicadvocate. Cybin is a biopharmaceutical company focused onprogressing Psychedelics to Therapeutics(TM), and the ChopraFoundation is a not-for-profit organization dedicated to improvinghealth and well-being.

To view the full press release, visit

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Friday's trading session at $0.4595, up -0.541126%, on 1,492,091 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2649 /$1.14 .

Recent News

Jupiter Wellness Inc. (NASDAQ: JUPW)

The QualityStocks Daily Newsletter would like to spotlight Jupiter Wellness Inc. (NASDAQ: JUPW).

While living in urban areas brings plenty of benefits to itsresidents, it is not always beneficial to their health. Forstarters, urban dwellers are exposed to a lot more air pollution compared to people living in rural areas. They are also morelikely to be infected with communicable diseases due to the dense populations of most cities. And now a recent study has revealed that increased noise levels in urban areas can domore than just annoy residents. The study found that people aremore likely to develop tinnitus if they are exposed to traffic noise in their homes. People living near busy roads are more likely tohave increased stress levels and poor sleep schedules. Exposure tosuch conditions for extended periods may increase your risk ofdeveloping tinnitus, the study found. Scientists from theUniversity of Southern Denmark’s Mærsk Mc-Kinney Møller Institute and the Department of Clinical Research reviewed data from some 3.5million Danes to determine the effect of continued exposure totraffic noise. In the meantime, for-profit entities such as Jupiter Wellness Inc. (NASDAQ: JUPW) are focused on developing treatments for tinnitus so that thosewho are affected can get some respite from the relentless ravagesof this condition.

Jupiter Wellness Inc. (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (OTC) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary products.

Jupiter Wellness’s product pipeline, backed by clinical research to ensure efficacy, addresses a range of underserved conditions. The company’s revenue is generated through a combination of OTC and consumer product sales, contract research agreements, and licensing royalties.

Jupiter Wellness was formed in 2018 and is headquartered in Jupiter, Florida.

Products with Purpose

Jupiter Wellness’s product pipeline currently targets a variety of indications with underserved needs. These include:

  • Hair Loss – Jupiter Wellness’s Minoxidil Booster is a topical treatment that’s been clinically shown to increase the enzymes needed for minoxidil to work by up to 7x over a two-week period. The product has been licensed to Taisho, a $2.6 billion revenue company and Japan’s leading seller of minoxidil products, which expects to launch it commercially in 2023. The product is licensed to India-based Cosmofix Technovation Pvt. Ltd. and Sanpellegrino Cosmetics, and additional licensing opportunities are being pursued.
  • Psoriasis & VitiligoPhotocil safely and effectively permits phototherapy treatments at home by blocking harmful radiation and permitting the passage of therapeutic UV radiation. The product has been licensed abroad and is currently being launched commercially in India by Eris Oaknet Healthcare and Cosmofix Technovation under the brand name PhotoFirst. The product is also available in the U.S., and the company is working to find new partners in dermatology for expanded distribution.
  • Jellyfish Protection SunscreenNoStingz is a topical protection from jellyfish, sea lice, and UVA/UVB rays. It provides an effective barrier against the stinging mechanism of jellyfish cnidocytes, preventing the delivery of venom to the victim. NoStingz is currently available online through Amazon and Walmart, as well as in select stores.
  • EczemaJW-100 is a pre-revenue topical treatment for atopic dermatitis (eczema). In prior studies, JW-100 cleared or reduced eczema symptoms following 2 weeks of use. Results suggest that JW-100 may potentially prove superior to existing prescription drugs. It is currently being evaluated in a Phase 3, double-blind, placebo-controlled multicenter trial.
  • BurnsJW-300 is a pre-revenue topical treatment for first-degree burns and sun exposure. In prior studies, JW-300 was shown to significantly lower the incidence of burns in patients exposed to UV radiation. It is currently being evaluated for sale as an “after sun” consumer product.
  • Cold SoresJW-400 is a pre-revenue topical treatment of herpes labialis (cold sores). A phase 1, double-blind, placebo-controlled investigational study is currently being planned for JW-400.
  • Sexual WellnessJW-500 is a pre-revenue topical treatment for female libido loss. In clinical studies, the topical formulation improved nipple sensitivity and alleviated associated sexual problems. Jupiter Wellness plans to file for a pre-IND meeting with the U.S. FDA within the next 12 months and intends to seek Orphan Drug Designation.
  • COVID-19-Induced TinnitusJW-600 is currently being evaluated in a triple-blind clinical study. Up to 15% of patients recovering from COVID-19 have experienced post-acute COVID-19-induced tinnitus

Management Team

Brian John is the CEO of Jupiter Wellness. For the past 20 years, he has been an investor and advisor to companies around the globe. He is the founder of a successful financial consulting firm specializing in helping emerging growth companies and has worked with hundreds of companies in dozens of countries over the last 25 years. Mr. John also serves on the board of directors of The Learning Center at the Els Center of Excellence – a school for children with autism in Jupiter, Florida.

Doug McKinnon is the CFO of Jupiter Wellness. His 35+ year professional career includes financial, advisory, and operational experience across a broad spectrum of industry sectors, including oil and gas, technology, cannabis, and communications. He has served in C-Level positions in both private and public sectors, including as chairman and CEO of an American-stock-exchange-traded company; as VP – Chief Administrative Officer of a $12-billion-market-cap Nasdaq-traded company; as CFO of several publicly-held U.S., Canadian and Australian companies; and as CEO/CFO of various other private enterprises.

Dr. Glynn Wilson is the Chief Scientific Officer of Jupiter Wellness. He brings to the company an extensive background of success in corporate management and product development with tenures in both multinational and start-up biotech organizations. He was formerly Head of Drug Delivery at SmithKline Beecham Pharmaceuticals; Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals; and Founder, CEO, and Chairman of TapImmune Inc., which became Marker Therapeutics through a merger. At TapImmune, he licensed cancer vaccine technology platforms and established the clinical pipeline.

Jupiter Wellness Inc. (NASDAQ: JUPW), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

Company’s investigational drug is being tested for the first timeever on humans in an FDA-approved study

In phase 1 studies, IGC-AD1 shows potential to safely reducedebilitating symptoms

IGC is actively building a portfolio of both cannabis-based andmanufactured molecules that can address multiple areas of unmetmedical needs

In groundbreaking work that establishes its commitment to being apioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is beingtested for the first time ever on humans in an FDA-approved study ( The company is developing its proprietary treatment, IGC-AD1,hoping to provide relief to the 55 million people worldwidestruggling with agitation in dementia that results fromAlzheimer’s.

The Substance Abuse and Mental Health Services Administration(SAMHSA), a branch of the U.S. Department of Health and HumanServices, has released a new advisory warning about the possible side effects, harms,and unknowns of CBD. The federal agency also makes the implication that cannabisdispensaries may sell safer products than gas stations and otherstores. The cannabinoid product has been available on store shelvessince Congress approved the use of hemp in the 2018 Farm Act, andSAMHSA reports that demand for it is still rising. According to SAMHSA’s advisory, a variety of form factors, such as CBD-infused foods, topicals,fabrics and drinks, are now available at an estimated 270,000retail stores countrywide. According to the advisory, which quotes a survey done by prescription discount planSingleCare, one in every three Americans reported using cannabinoid products in 2020. As a result of itswidespread use, the agency urges that people be aware of the risksand dangers involved with using CBD products as well as the commonmisconceptions surrounding them. The medicinal potential ofcannabis has drawn the attention of many entities, such as India Globalization Capital Inc. (NYSE American: IGC), which have invested heavily into studying these substances withthe aim of commercializing FDA-approved formulations from them.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Friday's trading session at $0.3848, up -0.051948%, on 102,722 volume with 00 trades. The average volume for the last 3 months is 97,102 and the stock's 52-week low/high is $0.2785 /$1.16 .

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a North American transportation logistics technology company,understands the direct relationship between successful, efficienttrade and logistics services. “Through its in-house technologies,which are powered by artificial intelligence (‘AI’), Fr8Tech seeksto modernize operations for shippers and carriers in Mexico, Canadaand the U.S. [the USMCA region] by optimizing logistics, reducingtransportation costs and making fleets more efficient. All thesebenefits are anchored in an innovative digital freight matchingtechnology: the Fr8App B2B marketplace. Fr8App is a central,cloud-based control center that connects shippers and carriers,matching them based on the former’s unique shipping needs and thelatter’s carrying capacity and reliability. To put it simply,Fr8App streamlines the once complex process of over-the-road(‘OTR’) shipping,” a recent article reads. “The Fr8App marketplaceis linked to some of Fr8Tech’s other software solutions, addingextra value to the users… As the USMCA continues to spur tradeamong North American countries, Fr8Tech is providing supportstructures that boost efficiency.”

To view the full article, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $0.3015, up -5.7812%, on 3,111,032 volume with 00 trades. The average volume for the last 3 months is 3.024M and the stock's 52-week low/high is $0.1799 /$3.60 .

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

Hillcrest (CSE: HEAT) (OTCQB: HLRTF) has emerged on the electric vehicle (“EV”) scene with innovationstackling heat and power issues that sap efficiency. “The good thingfor consumers is that innovation is making electric cars and trucksbetter at the engineering level. Vancouver-based Hillcrest raisedthe bar in the EV power inverter industry, eliminating traditionaltrade-offs regarding heat generation and electromagneticcompatibility (‘EMC’) that have plagued engineers for years. Thecompany uses a combination of hardware and software to unlockhigher switching frequencies resulting in improved power systemperformance and reliability without compromising efficiency,” arecent article reads. “Conventional traction inverters are a stableof EVs. Hillcrest has developed a flexible, single-inverterarchitecture that can be applied at nearly every stage of theelectrification ecosystem, from renewable energy generation throughthe charging and operation of an EV to provide full-cycleefficiency and performance improvements. Hillcrest’s flagshipcommercial prototype is a 250 kW|800V Hillcrest SiC high-efficiencytraction inverter that is ideal for electrification. While EVs arethe low-hanging fruit and a massive market opportunity, Hillcrest’sinverters have applications across an array of motors, generatorsand throughout the renewable energy space.”

To view the full article, visit

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Friday's trading session at $0.0599, up -5.0713%, on 16,000 volume with 00 trades. The average volume for the last 3 months is 16,000 and the stock's 52-week low/high is $0.0584 /$0.1468 .

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.